Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB-003B
- Development stage
- Preclinical
- Lead developer
- Therabene
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Parenteral
01
Overview
TB-003B is a preclinical-stage proteolysis-targeting chimera (PROTAC) designed to induce the targeted degradation of cyclin-dependent kinase 9 (CDK9). Developed by Therabene, it serves as a backup molecule to their lead candidate, TB-008. CDK9 is a key component of the positive transcription elongation factor b (P-TEFb) complex, which regulates the transcription of short-lived proteins such as c-Myc and MCL-1 that are often dysregulated in various malignancies. By utilizing the PROTAC modality, TB-003B aims to achieve more potent and sustained inhibition of CDK9 signaling compared to traditional small-molecule inhibitors. The program is being explored for potential applications in oncology, autoimmune disorders, and viral diseases.
- Other names
- TB-003BTB003BTB 003B
02
Targets
CDK9 (Cyclin-dependent kinase 9)CRBN (Cereblon)
Beyond the preview
Go deeper on TB-003B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB-003B.